WILLIAM ROSE - 07 Jun 2023 Form 4 Insider Report for REATA PHARMACEUTICALS INC

Role
Director, Member of 10% owner group, 10%+ Owner
Signature
/s/ Charles E. Gale, attorney-in-fact for William E. Rose
Issuer symbol
N/A
Transactions as of
07 Jun 2023
Net transactions value
+$79,943
Form type
4
Filing time
09 Jun 2023, 17:00:09 UTC
Previous filing
10 Jun 2022
Next filing
24 Aug 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RETA Stock Option (right-to-buy) Award $0 +4,275 $0.000000 4,275 07 Jun 2023 Class A common stock 4,275 $93.61 Direct F1
transaction RETA Stock Option (right-to-buy) Award $79,943 +1,085 $73.68 1,085 07 Jun 2023 Class A common stock 1,085 $93.61 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options vest in four equal installments on September 7, 2023, December 7, 2023, March 7, 2024, and June 5, 2024, subject to continued service through each vesting date.
F2 These options were issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of future director fees of $79,945.